Mesa Laboratories MLAB Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $8.85M-38.4% | $14.37M+3.3% | $13.92M+21.2% | $11.49M-9.0% | $12.62M+3.1% | |
| Clinical Genomics | $12.18M+3.5% | $11.77M+5.6% | $11.14M+8.2% | $10.3M-10.5% | $11.51M-9.1% | |
| Gross Profit by Business | ||||||
| Biopharmaceutical Development | $5.2M-41.7% | $8.92M+9.7% | $8.13M+28.9% | $6.31M-13.0% | $7.25M-3.9% | |
| Clinical Genomics | $7.39M+3.9% | $7.11M+16.7% | $6.1M+12.4% | $5.43M-14.2% | $6.33M-9.0% | |
| Cost Of Revenue by Business | ||||||
| Biopharmaceutical Development | $3.65M-33.1% | $5.45M-5.8% | $5.79M+11.8% | $5.18M-3.5% | $5.37M+14.3% | |
| Clinical Genomics | $4.79M+2.9% | $4.65M-7.7% | $5.04M+3.5% | $4.87M-6.0% | $5.19M-9.3% | |
| Cost Of Revenue Other by Business | ||||||
| Biopharmaceutical Development | $3.2M-35.9% | $4.99M-6.8% | $5.35M+13.4% | $4.72M-4.7% | $4.95M+15.2% | |
| Clinical Genomics | $4.47M+3.3% | $4.33M-7.9% | $4.7M+4.1% | $4.52M-6.5% | $4.83M-12.4% | |
| Inventory Net by Business | ||||||
| Biopharmaceutical Development | $6.51M+10.6% | $5.89M+3.0% | $5.72M-3.9% | $5.94M+20.5% | $4.93M— | |
| Clinical Genomics | $8.32M-5.0% | $8.75M-3.9% | $9.1M-9.0% | $10.01M+2.4% | $9.78M— | |
| Cost Of Goods And Services Sold Depreciation by Business | ||||||
| Biopharmaceutical Development | $65K-26.1% | $88K+33.3% | $66K-25.8% | $89K+18.7% | $75K+19.0% | |
| Clinical Genomics | $127K-4.5% | $133K-12.5% | $152K-8.4% | $166K0.0% | $166K+774% | |
| Goodwill by Business | ||||||
| Biopharmaceutical Development | $49.67M-2.3% | $50.82M+1.4% | $50.1M+0.5% | $49.84M+3.4% | $48.21M— | |
| Clinical Genomics | $17.12M0.0% | $17.12M+0.3% | $17.08M+0.1% | $17.06M+0.8% | $16.93M— | |
| Cost Of Goods And Services Sold Amortization by Business | ||||||
| Biopharmaceutical Development | $386K+1.8% | $379K+1.1% | $375K+0.8% | $372K+8.1% | $344K+1.8% | |
| Clinical Genomics | $191K0.0% | $191K-0.5% | $192K+0.5% | $191K0.0% | $191K0.0% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Clinical Genomics | $0-100% | $44K+159% | $17K-87.4% | $135K+4,600% | -$3K0.0% | |
| Revenue by Product | ||||||
| Service | $12.2M+10.4% | $11.05M-2.1% | $11.29M+0.8% | $11.2M+2.2% | $10.96M+7.1% | |
| Revenue by Geography | ||||||
| CN | $4.06M-28.1% | $5.65M+6.2% | $5.32M-2.1% | $5.43M+7.7% | $5.04M-20.3% | |
| Other | $29.61M+0.1% | $29.59M+13.3% | $26.12M-1.3% | $26.47M+2.2% | $25.89M-0.6% | |
| US | $30.06M+0.6% | $29.89M+2.0% | $29.3M+6.0% | $27.65M-11.4% | $31.2M+2.4% | |
| Non-Current Assets by Geography | ||||||
| Non Us | $1.21M— | —— | —— | —— | $1.17M— | |
| SE | $10.86M— | —— | —— | —— | $11.63M— | |
| US | $29.89M— | —— | —— | —— | $29.2M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
